Literature DB >> 31955355

Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.

J Remon1, F Tabbò2, B Jimenez3, A Collazo3, J de Castro3, S Novello2.   

Abstract

Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients' outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.

Entities:  

Keywords:  ALK; Liquid biopsy; Next-generation; Non-small cell lung cancer; Sequential treatment

Mesh：

Substances：

Year:  2020        PMID： 31955355     DOI： 10.1007/s12094-020-02290-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  3 in total

Review 1.  Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won.

Authors:  Fabrizio Tabbò; Maria Lucia Reale; Paolo Bironzo; Giorgio V Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 2.  Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice.

Authors:  Paul Hofman
Journal:  Cells       Date:  2021-01-15       Impact factor: 6.600

3.  Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.

Authors:  Sergey V Orlov; Aglaya G Iyevleva; Elena A Filippova; Alexandra M Lozhkina; Svetlana V Odintsova; Tatiana N Sokolova; Natalia V Mitiushkina; Vladislav I Tiurin; Elena V Preobrazhenskaya; Alexandr A Romanko; Alexandr S Martianov; Alexandr O Ivantsov; Svetlana N Aleksakhina; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Transl Oncol       Date:  2021-05-21       Impact factor: 4.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.